Professor Paul Young
https://orcid.org/0000-0002-3428-3083MRINZ Deputy Director, Intensive Care Medicine Programme Lead, Oxygen Therapy co-Lead
BSc (Hons), MBChB, PhD, Grad Cert Crit Care Echo
Research programme(s) of involvement: Intensive Care Medicine; Oxygen Therapy; Clinical Management
Professional Positions and Memberships: Co-clinical leader and Intensive Care Specialist, Wellington Hospital Intensive Care Unit; Medical Director and Intensive Care Specialist, Wakefield Hospital Intensive Care Unit, Wakefield Hospital; Adjunct Professor (Research), Monash University, Melbourne Australia; Clinical Associate Professor in Critical Care, University of Melbourne, Melbourne, Australia; Fellow of the College of Intensive Care Medicine of Australia and New Zealand.
Research interests: Intensive Care Medicine; Oxygen Therapy; Clinical Management
About
Paul Young’s primary research interest is in the design and conduct of large-scale multicentre randomised clinical trials in the field of Intensive Care Medicine. An active member of the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), Paul is a leading member of the international intensive care research community.
Alongside his role at the MRINZ, Paul is the Medical Director of the Wakefield Hospital ICU and co-clinical leader of the Intensive Care Research Unit at Wellington Hospital. Paul is Clinical Associate Professor, Department of Critical Care, at the University of Melbourne, an Adjunct Professor at the Australian and New Zealand Intensive Care Research Centre, Monash University, and the Associate Editor for Critical Care and Resuscitation, the highest impact journal in the field of Intensive Care Medicine outside the US and Europe.
Involved in research collaborations with colleagues worldwide, Paul has published over 250 peer-reviewed journal articles, including numerous high impact publications in the New England Journal of Medicine, the Lancet, and the Journal of the American Medical Association. You can follow Paul’s clinical trial research on Twitter @DogICUma.